Trial Profile
The Effectivity and Toxicity of Methylsulfonic Apatinib for Extensively Pre-treated Advanced Sarcoma: a Multicentric Retrospective Study in China
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Chondrosarcoma; Ewing's sarcoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 11 Apr 2018 New trial record